The RadComp Study
RadComp, short for Radiotherapy Comparative Effectiveness, compares two types of standard care radiation therapy for locally advanced breast cancer-- Photon Therapy (pronounced “fo-tahn”) and Proton Therapy (pronounced “pro-tahn”).
The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety.
These objectives were chosen as study priorities by breast cancer patients themselves.
You may be eligible for this study if you
If you decide to take part in this study this is what your participation will look like:
Group 1: Receives PHoton Therapy once a day, 5 days a week, for 5 to 7 weeks
Group 2: Receives PRoton Therapy once a day, 5 days a week, for 5 to 7 weeks
Randomization is a technique to improve the quality and fairness of studies. You have a 50/50 chance of getting into either treatment group -- like a coin flip. Assigning you to a group helps makes sure that each group has a similar mix of patients and is only done when doctors are not sure whether one treatment is better than the other. Both you and your doctor will be told which treatment you will get following your signed consent.
For more general information, visit our FAQs or go on ClinicalTrials.gov and refer to this study by the name: “Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial” or by its ClinicalTrials.gov identifier: NCT02603341.
PCORI Acknowledgement: Research reported in this study website was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-1403-12804).
PCORI Disclaimer: The views, statements, and opinions presented in this study website are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.